Insights from Cutting-Edge Research

The relationship between insulin-like growth factor 1 (IGF-1) and longevity has captivated scientists for decades. Once celebrated for its role in growth and cellular repair, IGF-1 now sits at the center of a scientific paradox: while it is essential for development, emerging evidence suggests that lower levels of this hormone may be linked to extended lifespan in humans and other species. This blog post explores the latest research on IGF-1’s dual role in aging, examining how its effects shift across the lifespan, vary by gender, and interact with other biological systems like growth hormone (GH) and autophagy.

IGF-1’s Evolutionary Role and the Longevity Paradox

IGF-1 is a hormone structurally similar to insulin, playing a critical role in growth during childhood and maintaining tissue homeostasis in adulthood. It promotes cell proliferation, inhibits apoptosis, and supports metabolic functions. However, its potent growth-stimulating properties have also implicated it in age-related diseases, particularly cancer5.

In animal models, reduced IGF-1 signaling has been associated with remarkable lifespan extensions. For instance, mice with mutations in the IGF-1 receptor (IGF-1R) live up to 33% longer than controls, though these effects are more pronounced in females5. Similarly, worms and flies with dampened IGF-1 pathways exhibit delayed aging5. Yet, translating these findings to humans has proven contentious. While centenarians often exhibit genetic variants linked to reduced IGF-1 activity6, studies in older adults show conflicting results, with some linking low IGF-1 to frailty and others to longevity24.

The Gender Divide: IGF-1’s Sex-Specific Effects

One of the most intriguing discoveries is the gender-specific impact of IGF-1 on survival. In a landmark study of 184 nonagenarians, women with IGF-1 levels below the median (≤96 ng/mL) lived significantly longer than those with higher levels, while no such association existed in men24. This mirrors findings in rodents, where females with GH/IGF-1 pathway mutations consistently outlive males24.

The reasons for this disparity remain unclear. Hypotheses include interactions between IGF-1 and estrogen or sex-specific differences in tissue repair mechanisms. For example, IGF-1’s role in mammary gland development might increase cancer risk in females, thereby amplifying the survival benefit of lower levels2. Conversely, males may rely more on IGF-1 for maintaining muscle mass and cardiovascular health, offsetting its potential downsides5.

Cancer Context: IGF-1’s Double-Edged Sword

The relationship between IGF-1 and cancer mortality further complicates its role in aging. Among individuals with a history of cancer, lower IGF-1 levels correlate with significantly longer survival—nearly 49.6 months versus 20.7 months in those with elevated levels24. This aligns with IGF-1’s known role in promoting tumor growth and metastasis by stimulating cell proliferation and inhibiting apoptosis5.

However, IGF-1’s effects are not universally detrimental. In healthy cells, it maintains mitochondrial function and activates mitophagy—a process that clears damaged mitochondria to prevent cellular aging3. For instance, IGF-1 treatment in aged smooth muscle cells reduced DNA damage, boosted mitochondrial membrane potential, and delayed senescence by upregulating pathways involving Nrf2 and Sirt33. Thus, IGF-1 may act as a “Goldilocks” molecule: essential for cellular repair but harmful in excess, particularly in the presence of cancer.

The Growth Hormone Connection: Is IGF-1 Just a Middleman?

Recent studies suggest that GH, not IGF-1, might be the primary longevity regulator. Mice with GH receptor deficiencies live longer and show fewer age-related diseases, even when IGF-1 levels are only moderately reduced1. In contrast, directly targeting IGF-1 signaling yields inconsistent results, with lifespan extensions being smaller and more variable15.

This divergence highlights GH’s broader metabolic influence. Reduced GH signaling enhances insulin sensitivity, reduces inflammation, and improves stress resistance—effects that are less pronounced in IGF-1-focused interventions1. For example, transgenic mice expressing a GH antagonist exhibited no lifespan increase despite lower IGF-1 levels, underscoring GH’s independent role1.

The U-Shaped Curve: Age Modifies IGF-1’s Impact

Emerging data reveal that IGF-1’s relationship with mortality follows a U-shaped curve, dependent on age. In younger populations, moderate IGF-1 levels protect against cardiovascular disease and diabetes, supporting growth and metabolic health. However, in older adults, both excessively high and low levels correlate with increased mortality6.

This dual role reflects shifting biological priorities across the lifespan. In youth, IGF-1 drives development and tissue repair. In later years, its proliferative effects may accelerate cancer progression while impairing autophagy—a cellular “cleanup” process critical for longevity6. Centenarians often strike a balance, maintaining just enough IGF-1 to support vital functions without fueling age-related pathologies56.

Genetic Clues: The Centenarian Advantage

Human longevity studies have identified genetic variants that dampen IGF-1 signaling. For example, mutations in the IGF-1 receptor (IGF1R) are more common in centenarians, conferring partial resistance to IGF-1’s growth signals25. Similarly, polymorphisms in GH-related genes, such as the d3-GHR deletion, are linked to a 10-year increase in life expectancy5.

These genetic adaptations mirror the effects of caloric restriction (CR), a proven longevity intervention. CR reduces IGF-1 levels, shifting metabolism toward maintenance and repair—a pattern also observed in long-lived individuals5. Both strategies appear to slow cellular aging by enhancing stress resistance and reducing senescent cell accumulation35.

Conclusion: Embracing Complexity in the Quest for Longevity

The IGF-1-longevity puzzle defies simple explanations. While lower IGF-1 levels predict extended survival in certain contexts—particularly among women and cancer survivors—its role varies by age, gender, and health status. GH’s independent effects and the U-shaped mortality curve further complicate the picture, suggesting that optimal IGF-1 levels are context-dependent.

Future research should prioritize personalized approaches, exploring how IGF-1 interacts with sex hormones, genetic backgrounds, and lifestyle factors. Therapeutic strategies might involve timed interventions: maintaining IGF-1 in youth to support growth and lowering it in later life to mitigate cancer risks. As we unravel these nuances, IGF-1 remains a compelling target for extending healthspan—not just lifespan—in our aging population.

Citations:

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC9434454/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4116456/
3. https://onlinelibrary.wiley.com/doi/10.1155/2020/4939310
4. https://onlinelibrary.wiley.com/doi/10.1111/acel.12213
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC6367275/
6. https://www.aging-us.com/article/204257/pdf
7. https://www.nature.com/articles/s41467-018-04805-5
8. https://jme.bioscientifica.com/view/journals/jme/61/1/JME-18-0093.xml
9. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1291812/full
10. http://www.aging-us.com/article/100071/text
11. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00027/full
12. https://www.pnas.org/doi/10.1073/pnas.1002696107
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4074016/
14. https://montefioreeinstein.org/news/2021/09/24/igf-1-hormone-good-young-bad-old
15. https://www.nature.com/articles/nrendo.2013.67
16. https://academic.oup.com/biomedgerontology/article/67A/6/626/584011